

BEIKE BIOTECHNOLOGY

Patient Case Study

Olivopontocerebellar Atrophy

Male, 58 years old, July - August 2011

Background

Age: 58 years old

Sex: Male

Nationality: American

Date of Admission: July 20, 2011

Date of Discharge: August 18, 2011

Treatment Center: Qingdao Chengyang People's Hospital, Qingdao, China

Diagnosis on Admission: Olivopontocerebellar Atrophy

Condition On Admission

The patient's main complaint upon admission was of an unsteady gait for the previous 20 years and slurred speech for the last 15 years. Physical examination showed his consciousness, perception and judgment skills were all normal but his speech was slurred. Overall muscle tone was normal and muscle strength in the upper limbs was normal. The muscle strength scores in the lower limbs were inferior, with the left side weaker than the right. Deep tendon reflexes were normal and deep and shallow sensations were also normal. The finger-to-nose test was slow and unstable and the heel-knee-tibia test was also unstable and shaky.

Treatment Schedule

Patient received 6 umbilical cord blood derived stem cell packets (UCBSC) by intravenous (IV) and lumbar puncture (LP), as per schedule below:

Number	Date	Cell Type	Delivery Method	Side Effects
1	July 22, 2011	UCBSC	IV	none reported
2	July 27, 2011	UCBSC	LP	none reported
3	August 1, 2011	UCBSC	LP	none reported
4	August 5, 2011	UCBSC	LP	none reported
5	August 10, 2011	UCBSC	LP	none reported
6	August 15, 2011	UCBSC	IV	none reported

Condition On Discharge

The doctors noted the patient had gained muscle strength in the lower limbs and had better balance and stability. He was recommended to continue rehabilitation exercises and movements upon returning home.

Follow Up Information

Condition 3 months after treatment: The patient completed the 3-month follow up report and felt he was having significant improvements in his physical condition. He was also continuing to gain improvements at this time. Please see excerpt below from his follow up report:

Symptom	Parents' Assessment of Improvement
Trunk control	Moderate improvement
Balance	Moderate improvement
Movement in general	Moderate improvement
Walking	Moderate improvement
Crawling	Significant improvement
Standing up	Moderate improvement
Spasticity	Moderate improvement
Overall strength	Significant improvement
Limb muscle strength	Significant improvement
Trunk muscle strength	Moderate improvement
Range of movement	Significant improvement
Fine motor control	Moderate improvement
Hand control	Significant improvement
Speech	Significant improvement

Condition 12 months after treatment: The patient also completed a follow up report 12 months after his treatment to report any additional changes since on his 3-month report. At this time he felt his improvements had stabilized, the progression of his condition had slowed and he was satisfied with the overall treatment outcome. An excerpt of this report is on the next page.

Please see the excerpt below from the patient's twelve month assessment.

Symptom	Parents' Assessment of Improvement
Trunk control	Small improvement
Balance	No improvement
Movement in general	Moderate improvement
Walking	Small improvement
Crawling	Moderate improvement
Standing up	Small improvement
Spasticity	Moderate improvement
Overall strength	Moderate improvement
Limb muscle strength	Moderate improvement
Trunk muscle strength	Moderate improvement
Range of movement	Moderate improvement
Fine motor control	Moderate improvement
Hand control	Moderate improvement
Speech	Small improvement

BEIKE BIOTECHNOLOGY CO., LTD.

East Block, 2nd Floor, Yuanxing Technology Building, #1 Songpingshan Road
Nanshan District, Shenzhen, Guangdong, China

Tel: +86-755-8630-9277 Email: info@beikebiotech.com Fax: +86-755-8630-9309 Web: www.beikebiotech.com